Copyright Reports & Markets. All rights reserved.

Global IBS-C Drugs Sales Market Report 2021

Request for Sample of this report
Buy now

1 IBS-C Drugs Market Overview

  • 1.1 IBS-C Drugs Product Scope
  • 1.2 IBS-C Drugs Segment by Type
    • 1.2.1 Global IBS-C Drugs Sales by Type (2016 & 2021 & 2027)
    • 1.2.2 Linaclotide
    • 1.2.3 Lubiprostone
    • 1.2.4 Osmotic Laxatives
    • 1.2.5 Stimulant Laxatives
    • 1.2.6 Others
  • 1.3 IBS-C Drugs Segment by Application
    • 1.3.1 Global IBS-C Drugs Sales Comparison by Application (2016 & 2021 & 2027)
    • 1.3.2 Hospital Pharmacies
    • 1.3.3 Retail Pharmacies
    • 1.3.4 Online Pharmacies
  • 1.4 IBS-C Drugs Market Estimates and Forecasts (2016-2027)
    • 1.4.1 Global IBS-C Drugs Market Size in Value Growth Rate (2016-2027)
    • 1.4.2 Global IBS-C Drugs Market Size in Volume Growth Rate (2016-2027)
    • 1.4.3 Global IBS-C Drugs Price Trends (2016-2027)

2 IBS-C Drugs Estimates and Forecasts by Region

  • 2.1 Global IBS-C Drugs Market Size by Region: 2016 VS 2021 VS 2027
  • 2.2 Global IBS-C Drugs Retrospective Market Scenario by Region (2016-2021)
    • 2.2.1 Global IBS-C Drugs Sales Market Share by Region (2016-2021)
    • 2.2.2 Global IBS-C Drugs Revenue Market Share by Region (2016-2021)
  • 2.3 Global IBS-C Drugs Market Estimates and Forecasts by Region (2022-2027)
    • 2.3.1 Global IBS-C Drugs Sales Estimates and Forecasts by Region (2022-2027)
    • 2.3.2 Global IBS-C Drugs Revenue Forecast by Region (2022-2027)
  • 2.4 Geographic Market Analysis: Market Facts & Figures
    • 2.4.1 North America IBS-C Drugs Estimates and Projections (2016-2027)
    • 2.4.2 Europe IBS-C Drugs Estimates and Projections (2016-2027)
    • 2.4.3 China IBS-C Drugs Estimates and Projections (2016-2027)
    • 2.4.4 Japan IBS-C Drugs Estimates and Projections (2016-2027)
    • 2.4.5 Southeast Asia IBS-C Drugs Estimates and Projections (2016-2027)
    • 2.4.6 India IBS-C Drugs Estimates and Projections (2016-2027)

3 Global IBS-C Drugs Competition Landscape by Players

  • 3.1 Global Top IBS-C Drugs Players by Sales (2016-2021)
  • 3.2 Global Top IBS-C Drugs Players by Revenue (2016-2021)
  • 3.3 Global IBS-C Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in IBS-C Drugs as of 2020)
  • 3.4 Global IBS-C Drugs Average Price by Company (2016-2021)
  • 3.5 Manufacturers IBS-C Drugs Manufacturing Sites, Area Served, Product Type
  • 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global IBS-C Drugs Market Size by Type

  • 4.1 Global IBS-C Drugs Historic Market Review by Type (2016-2021)
    • 4.1.1 Global IBS-C Drugs Sales Market Share by Type (2016-2021)
    • 4.1.2 Global IBS-C Drugs Revenue Market Share by Type (2016-2021)
    • 4.1.3 Global IBS-C Drugs Price by Type (2016-2021)
  • 4.2 Global IBS-C Drugs Market Estimates and Forecasts by Type (2022-2027)
    • 4.2.1 Global IBS-C Drugs Sales Forecast by Type (2022-2027)
    • 4.2.2 Global IBS-C Drugs Revenue Forecast by Type (2022-2027)
    • 4.2.3 Global IBS-C Drugs Price Forecast by Type (2022-2027)

5 Global IBS-C Drugs Market Size by Application

  • 5.1 Global IBS-C Drugs Historic Market Review by Application (2016-2021)
    • 5.1.1 Global IBS-C Drugs Sales Market Share by Application (2016-2021)
    • 5.1.2 Global IBS-C Drugs Revenue Market Share by Application (2016-2021)
    • 5.1.3 Global IBS-C Drugs Price by Application (2016-2021)
  • 5.2 Global IBS-C Drugs Market Estimates and Forecasts by Application (2022-2027)
    • 5.2.1 Global IBS-C Drugs Sales Forecast by Application (2022-2027)
    • 5.2.2 Global IBS-C Drugs Revenue Forecast by Application (2022-2027)
    • 5.2.3 Global IBS-C Drugs Price Forecast by Application (2022-2027)

6 North America IBS-C Drugs Market Facts & Figures

  • 6.1 North America IBS-C Drugs Sales by Company
    • 6.1.1 North America IBS-C Drugs Sales by Company (2016-2021)
    • 6.1.2 North America IBS-C Drugs Revenue by Company (2016-2021)
  • 6.2 North America IBS-C Drugs Sales Breakdown by Type
    • 6.2.1 North America IBS-C Drugs Sales Breakdown by Type (2016-2021)
    • 6.2.2 North America IBS-C Drugs Sales Breakdown by Type (2022-2027)
  • 6.3 North America IBS-C Drugs Sales Breakdown by Application
    • 6.3.1 North America IBS-C Drugs Sales Breakdown by Application (2016-2021)
    • 6.3.2 North America IBS-C Drugs Sales Breakdown by Application (2022-2027)

7 Europe IBS-C Drugs Market Facts & Figures

  • 7.1 Europe IBS-C Drugs Sales by Company
    • 7.1.1 Europe IBS-C Drugs Sales by Company (2016-2021)
    • 7.1.2 Europe IBS-C Drugs Revenue by Company (2016-2021)
  • 7.2 Europe IBS-C Drugs Sales Breakdown by Type
    • 7.2.1 Europe IBS-C Drugs Sales Breakdown by Type (2016-2021)
    • 7.2.2 Europe IBS-C Drugs Sales Breakdown by Type (2022-2027)
  • 7.3 Europe IBS-C Drugs Sales Breakdown by Application
    • 7.3.1 Europe 152 Sales Breakdown by Application (2016-2021)
    • 7.3.2 Europe 152 Sales Breakdown by Application (2022-2027)

8 China IBS-C Drugs Market Facts & Figures

  • 8.1 China IBS-C Drugs Sales by Company
    • 8.1.1 China IBS-C Drugs Sales by Company (2016-2021)
    • 8.1.2 China IBS-C Drugs Revenue by Company (2016-2021)
  • 8.2 China IBS-C Drugs Sales Breakdown by Type
    • 8.2.1 China IBS-C Drugs Sales Breakdown by Type (2016-2021)
    • 8.2.2 China IBS-C Drugs Sales Breakdown by Type (2022-2027)
  • 8.3 China IBS-C Drugs Sales Breakdown by Application
    • 8.3.1 China 177 Sales Breakdown by Application (2016-2021)
    • 8.3.2 China 177 Sales Breakdown by Application (2022-2027)

9 Japan IBS-C Drugs Market Facts & Figures

  • 9.1 Japan IBS-C Drugs Sales by Company
    • 9.1.1 Japan IBS-C Drugs Sales by Company (2016-2021)
    • 9.1.2 Japan IBS-C Drugs Revenue by Company (2016-2021)
  • 9.2 Japan IBS-C Drugs Sales Breakdown by Type
    • 9.2.1 Japan IBS-C Drugs Sales Breakdown by Type (2016-2021)
    • 9.2.2 Japan IBS-C Drugs Sales Breakdown by Type (2022-2027)
  • 9.3 Japan IBS-C Drugs Sales Breakdown by Application
    • 9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
    • 9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)

10 Southeast Asia IBS-C Drugs Market Facts & Figures

  • 10.1 Southeast Asia IBS-C Drugs Sales by Company
    • 10.1.1 Southeast Asia IBS-C Drugs Sales by Company (2016-2021)
    • 10.1.2 Southeast Asia IBS-C Drugs Revenue by Company (2016-2021)
  • 10.2 Southeast Asia IBS-C Drugs Sales Breakdown by Type
    • 10.2.1 Southeast Asia IBS-C Drugs Sales Breakdown by Type (2016-2021)
    • 10.2.2 Southeast Asia IBS-C Drugs Sales Breakdown by Type (2022-2027)
  • 10.3 Southeast Asia IBS-C Drugs Sales Breakdown by Application
    • 10.3.1 Southeast Asia K Pcs Sales Breakdown by Application (2016-2021)
    • 10.3.2 Southeast Asia K Pcs Sales Breakdown by Application (2022-2027)

11 India IBS-C Drugs Market Facts & Figures

  • 11.1 India IBS-C Drugs Sales by Company
    • 11.1.1 India IBS-C Drugs Sales by Company (2016-2021)
    • 11.1.2 India IBS-C Drugs Revenue by Company (2016-2021)
  • 11.2 India IBS-C Drugs Sales Breakdown by Type
    • 11.2.1 India IBS-C Drugs Sales Breakdown by Type (2016-2021)
    • 11.2.2 India IBS-C Drugs Sales Breakdown by Type (2022-2027)
  • 11.3 India IBS-C Drugs Sales Breakdown by Application
    • 11.3.1 India IBS-C Drugs Sales Breakdown by Application (2016-2021)
    • 11.3.2 India IBS-C Drugs Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in IBS-C Drugs Business

  • 12.1 Catalent Pharmaceuticals Solutions
    • 12.1.1 Catalent Pharmaceuticals Solutions Corporation Information
    • 12.1.2 Catalent Pharmaceuticals Solutions Business Overview
    • 12.1.3 Catalent Pharmaceuticals Solutions IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.1.4 Catalent Pharmaceuticals Solutions IBS-C Drugs Products Offered
    • 12.1.5 Catalent Pharmaceuticals Solutions Recent Development
  • 12.2 Nestle
    • 12.2.1 Nestle Corporation Information
    • 12.2.2 Nestle Business Overview
    • 12.2.3 Nestle IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.2.4 Nestle IBS-C Drugs Products Offered
    • 12.2.5 Nestle Recent Development
  • 12.3 Abbott Laboratories
    • 12.3.1 Abbott Laboratories Corporation Information
    • 12.3.2 Abbott Laboratories Business Overview
    • 12.3.3 Abbott Laboratories IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.3.4 Abbott Laboratories IBS-C Drugs Products Offered
    • 12.3.5 Abbott Laboratories Recent Development
  • 12.4 Synergy Pharmaceuticals
    • 12.4.1 Synergy Pharmaceuticals Corporation Information
    • 12.4.2 Synergy Pharmaceuticals Business Overview
    • 12.4.3 Synergy Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.4.4 Synergy Pharmaceuticals IBS-C Drugs Products Offered
    • 12.4.5 Synergy Pharmaceuticals Recent Development
  • 12.5 Sucampo Pharmaceuticals
    • 12.5.1 Sucampo Pharmaceuticals Corporation Information
    • 12.5.2 Sucampo Pharmaceuticals Business Overview
    • 12.5.3 Sucampo Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.5.4 Sucampo Pharmaceuticals IBS-C Drugs Products Offered
    • 12.5.5 Sucampo Pharmaceuticals Recent Development
  • 12.6 Novartis Pharma Ag
    • 12.6.1 Novartis Pharma Ag Corporation Information
    • 12.6.2 Novartis Pharma Ag Business Overview
    • 12.6.3 Novartis Pharma Ag IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.6.4 Novartis Pharma Ag IBS-C Drugs Products Offered
    • 12.6.5 Novartis Pharma Ag Recent Development
  • 12.7 Astellas Pharmaceuticals
    • 12.7.1 Astellas Pharmaceuticals Corporation Information
    • 12.7.2 Astellas Pharmaceuticals Business Overview
    • 12.7.3 Astellas Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.7.4 Astellas Pharmaceuticals IBS-C Drugs Products Offered
    • 12.7.5 Astellas Pharmaceuticals Recent Development
  • 12.8 Ardelyx, Inc
    • 12.8.1 Ardelyx, Inc Corporation Information
    • 12.8.2 Ardelyx, Inc Business Overview
    • 12.8.3 Ardelyx, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.8.4 Ardelyx, Inc IBS-C Drugs Products Offered
    • 12.8.5 Ardelyx, Inc Recent Development
  • 12.9 Synthetic Biologics, Inc
    • 12.9.1 Synthetic Biologics, Inc Corporation Information
    • 12.9.2 Synthetic Biologics, Inc Business Overview
    • 12.9.3 Synthetic Biologics, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.9.4 Synthetic Biologics, Inc IBS-C Drugs Products Offered
    • 12.9.5 Synthetic Biologics, Inc Recent Development
  • 12.10 Teva Pharmaceutical Industries
    • 12.10.1 Teva Pharmaceutical Industries Corporation Information
    • 12.10.2 Teva Pharmaceutical Industries Business Overview
    • 12.10.3 Teva Pharmaceutical Industries IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.10.4 Teva Pharmaceutical Industries IBS-C Drugs Products Offered
    • 12.10.5 Teva Pharmaceutical Industries Recent Development
  • 12.11 Bama-Geve, SLU
    • 12.11.1 Bama-Geve, SLU Corporation Information
    • 12.11.2 Bama-Geve, SLU Business Overview
    • 12.11.3 Bama-Geve, SLU IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.11.4 Bama-Geve, SLU IBS-C Drugs Products Offered
    • 12.11.5 Bama-Geve, SLU Recent Development
  • 12.12 Ferring BV
    • 12.12.1 Ferring BV Corporation Information
    • 12.12.2 Ferring BV Business Overview
    • 12.12.3 Ferring BV IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.12.4 Ferring BV IBS-C Drugs Products Offered
    • 12.12.5 Ferring BV Recent Development
  • 12.13 Ironwood Pharmaceuticals, Inc
    • 12.13.1 Ironwood Pharmaceuticals, Inc Corporation Information
    • 12.13.2 Ironwood Pharmaceuticals, Inc Business Overview
    • 12.13.3 Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.13.4 Ironwood Pharmaceuticals, Inc IBS-C Drugs Products Offered
    • 12.13.5 Ironwood Pharmaceuticals, Inc Recent Development
  • 12.14 Salix Pharmaceuticals Ltd
    • 12.14.1 Salix Pharmaceuticals Ltd Corporation Information
    • 12.14.2 Salix Pharmaceuticals Ltd Business Overview
    • 12.14.3 Salix Pharmaceuticals Ltd IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.14.4 Salix Pharmaceuticals Ltd IBS-C Drugs Products Offered
    • 12.14.5 Salix Pharmaceuticals Ltd Recent Development
  • 12.15 Norgine B.V
    • 12.15.1 Norgine B.V Corporation Information
    • 12.15.2 Norgine B.V Business Overview
    • 12.15.3 Norgine B.V IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.15.4 Norgine B.V IBS-C Drugs Products Offered
    • 12.15.5 Norgine B.V Recent Development
  • 12.16 Prometheus Laboratories Inc
    • 12.16.1 Prometheus Laboratories Inc Corporation Information
    • 12.16.2 Prometheus Laboratories Inc Business Overview
    • 12.16.3 Prometheus Laboratories Inc IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.16.4 Prometheus Laboratories Inc IBS-C Drugs Products Offered
    • 12.16.5 Prometheus Laboratories Inc Recent Development
  • 12.17 Actavis Nordic A/S
    • 12.17.1 Actavis Nordic A/S Corporation Information
    • 12.17.2 Actavis Nordic A/S Business Overview
    • 12.17.3 Actavis Nordic A/S IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.17.4 Actavis Nordic A/S IBS-C Drugs Products Offered
    • 12.17.5 Actavis Nordic A/S Recent Development
  • 12.18 Albireo Pharma Inc
    • 12.18.1 Albireo Pharma Inc Corporation Information
    • 12.18.2 Albireo Pharma Inc Business Overview
    • 12.18.3 Albireo Pharma Inc IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.18.4 Albireo Pharma Inc IBS-C Drugs Products Offered
    • 12.18.5 Albireo Pharma Inc Recent Development
  • 12.19 Yuhan Corp
    • 12.19.1 Yuhan Corp Corporation Information
    • 12.19.2 Yuhan Corp Business Overview
    • 12.19.3 Yuhan Corp IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.19.4 Yuhan Corp IBS-C Drugs Products Offered
    • 12.19.5 Yuhan Corp Recent Development
  • 12.20 Astrazeneca Plc
    • 12.20.1 Astrazeneca Plc Corporation Information
    • 12.20.2 Astrazeneca Plc Business Overview
    • 12.20.3 Astrazeneca Plc IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.20.4 Astrazeneca Plc IBS-C Drugs Products Offered
    • 12.20.5 Astrazeneca Plc Recent Development
  • 12.21 The Menarini Group
    • 12.21.1 The Menarini Group Corporation Information
    • 12.21.2 The Menarini Group Business Overview
    • 12.21.3 The Menarini Group IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.21.4 The Menarini Group IBS-C Drugs Products Offered
    • 12.21.5 The Menarini Group Recent Development
  • 12.22 Ono Pharmaceutical Co., Ltd
    • 12.22.1 Ono Pharmaceutical Co., Ltd Corporation Information
    • 12.22.2 Ono Pharmaceutical Co., Ltd Business Overview
    • 12.22.3 Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 12.22.4 Ono Pharmaceutical Co., Ltd IBS-C Drugs Products Offered
    • 12.22.5 Ono Pharmaceutical Co., Ltd Recent Development

13 IBS-C Drugs Manufacturing Cost Analysis

  • 13.1 IBS-C Drugs Key Raw Materials Analysis
    • 13.1.1 Key Raw Materials
    • 13.1.2 Key Raw Materials Price Trend
    • 13.1.3 Key Suppliers of Raw Materials
  • 13.2 Proportion of Manufacturing Cost Structure
  • 13.3 Manufacturing Process Analysis of IBS-C Drugs
  • 13.4 IBS-C Drugs Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers

  • 14.1 Marketing Channel
  • 14.2 IBS-C Drugs Distributors List
  • 14.3 IBS-C Drugs Customers

15 Market Dynamics

  • 15.1 IBS-C Drugs Market Trends
  • 15.2 IBS-C Drugs Drivers
  • 15.3 IBS-C Drugs Market Challenges
  • 15.4 IBS-C Drugs Market Restraints

16 Research Findings and Conclusion

    17 Appendix

    • 17.1 Research Methodology
      • 17.1.1 Methodology/Research Approach
      • 17.1.2 Data Source
    • 17.2 Author List

    The global IBS-C Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global IBS-C Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

    Segment by Type
    Linaclotide
    Lubiprostone
    Osmotic Laxatives
    Stimulant Laxatives
    Others

    Segment by Application
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

    The IBS-C Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the IBS-C Drugs market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

    By Company
    Catalent Pharmaceuticals Solutions
    Nestle
    Abbott Laboratories
    Synergy Pharmaceuticals
    Sucampo Pharmaceuticals
    Novartis Pharma Ag
    Astellas Pharmaceuticals
    Ardelyx, Inc
    Synthetic Biologics, Inc
    Teva Pharmaceutical Industries
    Bama-Geve, SLU
    Ferring BV
    Ironwood Pharmaceuticals, Inc
    Salix Pharmaceuticals Ltd
    Norgine B.V
    Prometheus Laboratories Inc
    Actavis Nordic A/S
    Albireo Pharma Inc
    Yuhan Corp
    Astrazeneca Plc
    The Menarini Group
    Ono Pharmaceutical Co., Ltd

    Buy now